Floatz logo

Cediranib

Recurrent Colorectal Carcinoma

Mayo ClinicSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent Colorectal Carcinoma cohort.

Asset / SponsorPhaseRating
Atezolizumab
Academic and Community Cancer Research United
Phase 2B
INTERFERON ALFA-2B
Roswell Park Cancer Institute
Phase 2B
INTERLEUKIN-11
Fudan University
Phase 2CCC
Recombinant Human Thrombopoietin
Fudan University
Phase 2CCC
Odetiglucan
HiberCell, Inc.
Phase 1/2CCC

View all 17 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →